Skip to content

Study on the Omics Characteristics and Biomarkers of Rheumatoid Arthritis

Study on omics characteristics, immune cell clustering, and biomarkers in the blood of RA patients with different disease activity levels

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078530
Enrollment
Unknown
Registered
2023-12-12
Start date
2023-12-12
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

active stage group:None
remission stage group:None
Healthy control group:None

Sponsors

Shanghai Guanghua Hospital of Integrative Medicine Shanghai Guanghua Integrated Traditional Chinese and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 78 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.Willing to participate in this study and sign the informed consent form. 2.Age between 18 and 78 years. 3.Diagnosed as rheumatoid arthritis (RA) according to the 2010 classification criteria of the American College of Rheumatology (ACR) / the European League Against Rheumatism (EULAR).

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1.Patients with severe diseases affecting the heart, liver, brain, kidneys, and hematopoietic system (ALT or AST is more than 1.5 times higher than the upper limit of normal, and blood creatinine level is more than 1.5 times higher than the upper limit of normal). 2.Presence or history of malignant tumors. 3.Patients with concomitant other rheumatic diseases such as systemic lupus erythematosus, Sjögren's syndrome, ankylosing spondylitis, scleroderma, etc. 4.Patients with autoimmune intestinal diseases (e.g., Crohn's disease, ulcerative colitis). 5.Patients who are unable to cooperate or complete sample collection.

Design outcomes

Primary

MeasureTime frame
erythrocyte sedimentation rate ;Plasma metabolites;plasma protein;

Secondary

MeasureTime frame
CRP;anti-CCP;RF;fasting glucose;

Countries

China

Contacts

Public ContactXiao Lianbo

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

13701888178@163.com+86 137 0188 8178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026